Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23206105 | 0.84 | ALDH1A1 (0.35) | ALDH1A1TSHRPDE10ABCL2BCL2L1 | |
| SCHEMBL25860123 | 0.80 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL19625177 | 0.77 | CA1 (0.43) | ALDH1A1TSHRCYP3A4TP53TDP1 | |
| SCHEMBL5163137 | 0.77 | RAPGEF4 (0.41) | ALDH1A1TSHRGAANOS3NOS1 | |
| SCHEMBL11098641 | 0.76 | TSHR (0.53) | ALDH1A1TSHRCYP3A4GAAMAPK1 | |
| SCHEMBL22946251 | 0.74 | LMNA (0.42) | ALDH1A1GAABCL2BCL2L1MCL1 | |
| SCHEMBL807533 | 0.72 | CYP3A4 (0.52) | ALDH1A1TSHRCASP1CYP3A4POLB | |
| Hydrogen Peroxide SCHEMBL10882706 | 0.72 | LDHA (0.39) | ALDH1A1GAATP53TDP1BCL2 | |
| SCHEMBL10073285 | 0.72 | GABRA1 (0.42) | ALDH1A1BCL2BCL2L1MCL1BCL2L2 | |
| SCHEMBL10073282 | 0.72 | BCL2 (0.32) | BCL2BCL2L1MCL1BCL2L2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119573-A1 | GAS SEPARATION MEMBRANE, GAS SEPARATION MODULE, GAS SEPARATION APPARATUS, AND POLYIMIDE COMPOUND | FUJIFILM CORPORATION (JP) | 2023-04-20 | — | — | US | disclosed |
| US-20210332020-A1 | PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-10-28 | — | — | US | disclosed |
| US-9951046-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9603838-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | ALDH1A1 2736/4885TSHR 504/4885PDE10A 3159/4885 |
| US-20210332020-A1 | PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | ALDH1A1 3451/4885TSHR 4753/4885PDE10A 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.